A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

por Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O’Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Lai, Eseng
Publicado 2017

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup...

por Satake, Hironaga, Lee, Keun-Wook, Chung, Hyun Cheol, Lee, Jeeyun, Yamaguchi, Kensei, Chen, Jen-Shi, Yoshikawa, Takaki, Amagai, Kenji, Yeh, Kun-Huei, Goto, Masahiro, Chao, Yee, Lam, Ka-On, Han, Shi Rong, Shiratori, Shinichi, Shah, Sukrut, Shitara, Kohei
Publicado 2022

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase...

por Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol
Publicado 2019